Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 14/2013

01-09-2013 | Review Article

Pharmacological and Psychosocial Management of Mental, Neurological and Substance Use Disorders in Low- and Middle-Income Countries: Issues and Current Strategies

Authors: Jair de Jesus Mari, Luís Fernando Tófoli, Cristiano Noto, Li M. Li, Alessandra Diehl, Angélica M. Claudino, Mario F. Juruena

Published in: Drugs | Issue 14/2013

Login to get access

Abstract

Mental, neurological, and substance use disorders (MNS) are among the largest sources of medical disability in the world, surpassing both cardiovascular disease and cancer. The picture is not different in low- and middle-income countries (LAMIC) where the relative morbidity associated with MNS is increasing, as a consequence of improvement in general health indicators and longevity. However, 80 % of individuals with MNS live in LAMIC but only close to 20 % of cases receive some sort of treatment. The main aim of this article is to provide non-specialist health workers in LAMIC with an accessible guide to the affordable essential psychotropics and psychosocial interventions which are proven to be cost effective for treating the main MNS.
The MNS discussed in this article were selected on the basis of burden, following the key priority conditions selected by the Mental Health Action Programme (mhGAP) developed by the World Health Organization (WHO) (anxiety, stress-related and bodily distress disorders; depression and bipolar disorder; schizophrenia; alcohol and drug addiction; and epilepsy), with the addition of eating disorders, because of their emergent trend in middle-income countries. We review best evidence-based clinical practice in these areas, with a focus on drugs from the WHO Model List of Essential Medicines and the psychosocial interventions available in LAMIC for the management of these conditions in primary care. We do this by reviewing guidelines developed by prestigious professional associations and government agencies, clinical trials conducted in LAMIC and systematic reviews (including Cochrane reviews) identified from the main international literature databases (MEDLINE, EMBASE and PsycINFO).
In summary, it can be concluded that the availability and use of the psychotropics on the WHO Model List of Essential Medicines in LAMIC, plus an array of psychosocial interventions, can represent a cost-effective way to expand treatment of most MNS. The translation of these findings into policies can be achieved by relatively low supplementary funding, and limited effort engendered by governments and policy makers in LAMIC.
Literature
1.
Collins PY, Patel V, Joestl SS, et al. Grand challenges in global mental health. Nature. 2011;475(7354):27–30.PubMed
2.
3.
Hyman S, Chisholm D, Kessler R, et al. Mental disorders. In: Jamison DT, Breman JG, Measham AR, et al., editors. Disease control priorities in developing countries. Washington (DC): World Bank; 2006. p. 605–25.
4.
Gore FM, Bloem PJ, Patton GC, et al. Global burden of disease in young people aged 10–24 years: a systematic analysis. Lancet. 2011;377(9783):2093–102.PubMed
5.
Prince M, Patel V, Saxena S, et al. No health without mental health. Lancet. 2007;370(9590):859–77.PubMed
6.
Kohn R, Saxena S, Levav I, et al. The treatment gap in mental health care. Bull World Health Organ. 2004;82(11):858–66.PubMed
7.
Patel V, Farooq S, Thara R. What is the best approach to treating schizophrenia in developing countries? PLoS Med. 2007;4(6):e159.PubMed
8.
Demyttenaere K, Bruffaerts R, Posada-Villa J, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA. 2004;291(21):2581–90.PubMed
9.
10.
11.
Patel V, Thornicroft G. Packages of care for mental, neurological, and substance use disorders in low- and middle-income countries: PLoS Medicine Series. PLoS Med. 2009;6(10):e1000160.PubMed
12.
13.
Dua T, Barbui C, Clark N, et al. Evidence-based guidelines for mental, neurological, and substance use disorders in low- and middle-income countries: summary of WHO recommendations. PLoS Med. 2011;8(11):e1001122.PubMed
14.
Bass JK, Bornemann TH, Burkey M, et al. A United Nations General Assembly Special Session for mental, neurological, and substance use disorders: the time has come. PLoS Med. 2012;9(1):e1001159.PubMed
15.
16.
17.
Araya R, Rojas G, Fritsch R, et al. Treating depression in primary care in low-income women in Santiago, Chile: a randomised controlled trial. Lancet. 2003;361(9362):995–1000.PubMed
18.
Lara MA, Navarro C, Rubi NA, et al. Outcome results of two levels of intervention in low-income women with depressive symptoms. Am J Orthopsychiatry. 2003;73(1):35–43.PubMed
19.
Fulton BD, Scheffler RM, Sparkes SP, et al. Health workforce skill mix and task shifting in low income countries: a review of recent evidence. Hum Resour Health. 2011;9(1):1.PubMed
20.
Lund C, Tomlinson M, De Silva M, et al. PRIME: a programme to reduce the treatment gap for mental disorders in five low- and middle-income countries. PLoS Med. 2012;9(12):e1001359.PubMed
21.
22.
Araya R, Flynn T, Rojas G, et al. Cost-effectiveness of a primary care treatment program for depression in low-income women in Santiago, Chile. Am J Psychiatry. 2006;163(8):1379–87.PubMed
23.
Patel V, Weiss HA, Chowdhary N, et al. Lay health worker led intervention for depressive and anxiety disorders in India: impact on clinical and disability outcomes over 12 months. Br J Psychiatry. 2011;199(6):459–66.PubMed
24.
Patel V, Weiss HA, Chowdhary N, et al. Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trial. Lancet. 2010;376(9758):2086–95.PubMed
25.
Ormel J, VonKorff M, Ustun TB, et al. Common mental disorders and disability across cultures. Results from the WHO Collaborative Study on Psychological Problems in General Health Care. JAMA. 1994;272(22):1741–8.PubMed
26.
Kessler RC. Posttraumatic stress disorder: the burden to the individual and to society. J Clin Psychiatry. 2000;61(Suppl 5):4–12 discussion 3–4.PubMed
27.
Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety. 2002;16(4):162–71.PubMed
28.
Kessler RC, Angermeyer M, Anthony JC, et al. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization’s World Mental Health Survey Initiative. World Psychiatry. 2007;6(3):168–76.PubMed
29.
Gater R, Tansella M, Korten A, et al. Sex differences in the prevalence and detection of depressive and anxiety disorders in general health care settings: report from the World Health Organization Collaborative Study on Psychological Problems in General Health Care. Arch Gen Psychiatry. 1998;55(5):405–13.PubMed
30.
Fenske JN, Schwenk TL. Obsessive compulsive disorder: diagnosis and management. Am Fam Physician. 2009;80(3):239–45.PubMed
31.
Markarian Y, Larson MJ, Aldea MA, et al. Multiple pathways to functional impairment in obsessive-compulsive disorder. Clin Psychol Rev. 2010;30(1):78–88.PubMed
32.
Toole MJ, Waldman RJ. The public health aspects of complex emergencies and refugee situations. Annu Rev Public Health. 1997;18:283–312.PubMed
33.
Roberts B, Browne J. A systematic review of factors influencing the psychological health of conflict-affected populations in low- and middle-income countries. Glob Public Health. 2011;6(8):814–29.PubMed
34.
Keyes CL, Ryff CD. Somatization and mental health: a comparative study of the idiom of distress hypothesis. Soc Sci Med. 2003;57(10):1833–45.PubMed
35.
Escobar JI, Gureje O. Influence of cultural and social factors on the epidemiology of idiopathic somatic complaints and syndromes. Psychosom Med. 2007;69(9):841–5.PubMed
36.
Tofoli LF, Andrade LH, Fortes S. Somatization in Latin America: a review of the classification of somatoform disorders, functional syndromes and medically unexplained symptoms. Rev Bras Psiquiatr. 2011;33(Suppl 1):S59–80.PubMed
37.
Kroenke K. Physical symptom disorder: a simpler diagnostic category for somatization-spectrum conditions. J Psychosom Res. 2006;60(4):335–9.PubMed
38.
Fink P, Toft T, Hansen MS, et al. Symptoms and syndromes of bodily distress: an exploratory study of 978 internal medical, neurological, and primary care patients. Psychosom Med. 2007;69(1):30–9.PubMed
39.
Fink P, Schroder A. One single diagnosis, bodily distress syndrome, succeeded to capture 10 diagnostic categories of functional somatic syndromes and somatoform disorders. J Psychosom Res. 2010;68(5):415–26.PubMed
40.
Creed F, Henningsen P, Fink P. Medically unexplained symptoms, somatisation, and bodily distress: developing better clinical services. Cambridge: Cambridge University Press; 2011.
41.
Sartorius N, Ustun TB, Lecrubier Y, et al. Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care. Br J Psychiatry Suppl. 1996;30:38–43.PubMed
42.
Weich S, McBride O, Hussey D, et al. Latent class analysis of co-morbidity in the Adult Psychiatric Morbidity Survey in England 2007: implications for DSM-5 and ICD-11. Psychol Med. 2011;41(10):2201–12.PubMed
43.
Hanel G, Henningsen P, Herzog W, et al. Depression, anxiety, and somatoform disorders: vague or distinct categories in primary care? Results from a large cross-sectional study. J Psychosom Res. 2009;67(3):189–97.PubMed
44.
Gros DF, Magruder KM, Ruggiero KJ, et al. Comparing the symptoms of posttraumatic stress disorder with the distress and fear disorders. J Nerv Ment Dis. 2012;200(11):967–72.PubMed
45.
46.
47.
Bruckner TA, Scheffler RM, Shen G, et al. The mental health workforce gap in low- and middle-income countries: a needs-based approach. Bull World Health Organ. 2011;89(3):184–94.PubMed
48.
Koen N, Stein DJ. Pharmacotherapy of anxiety disorders: a critical review. Dialogues Clin Neurosci. 2011;13(4):423–37.PubMed
49.
National Institute for Clinical Excellence (NICE). Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults: management in primary, secondary and community care. London: National Institute for Clinical Excellence (Great Britain); 2011.
50.
Ipser JC, Kariuki CM, Stein DJ. Pharmacotherapy for social anxiety disorder: a systematic review. Expert Rev Neurother. 2008;8(2):235–57.PubMed
51.
Stein MB, Goin MK, Pollack MH, et al. Practice guideline for the treatment of patients with panic disorder. 2nd ed. Arlington: American Psychiatric Publishing; 2010.
52.
Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry. 2010;71(7):839–54.PubMed
53.
Baldwin D, Woods R, Lawson R, et al. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ. 2011;342:d1199.PubMed
54.
Lader M. Benzodiazepines revisited—will we ever learn? Addiction. 2011;106(12):2086–109.PubMed
55.
National Institute for Clinical Excellence (NICE). Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. London: National Institute for Clinical Excellence (Great Britain); 2005.
56.
Koran LM, Hanna GL, Hollander E, et al. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007;164(7 Suppl):5–53.PubMed
57.
Ipser JC, Carey P, Dhansay Y, et al. Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev. 2006;(4):CD005473.
58.
Blanco C, Raza MS, Schneier FR, et al. The evidence-based pharmacological treatment of social anxiety disorder. Int J Neuropsychopharmacol. 2003;6(4):427–42.PubMed
59.
Choy Y, Fyer AJ, Lipsitz JD. Treatment of specific phobia in adults. Clin Psychol Rev. 2007;27(3):266–86.PubMed
60.
Black DW. Efficacy of combined pharmacotherapy and psychotherapy versus monotherapy in the treatment of anxiety disorders. CNS Spectr. 2006;11(10 Suppl 12):29–33.PubMed
61.
Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev. 2003;(1):CD003383.
62.
Miyasaka LS, Atallah AN, Soares BG. Valerian for anxiety disorders. Cochrane Database Syst Rev. 2006;(4):CD004515.
63.
Miyasaka LS, Atallah AN, Soares BG. Passiflora for anxiety disorder. Cochrane Database Syst Rev. 2007;(1):CD004518.
64.
Faustino TT, Almeida RB, Andreatini R. Medicinal plants for the treatment of generalized anxiety disorder: a review of controlled clinical studies. Rev Bras Psiquiatr. 2010;32(4):429–36.PubMed
65.
Roberts NP, Kitchiner NJ, Kenardy J, et al. Early psychological interventions to treat acute traumatic stress symptoms. Cochrane Database Syst Rev. 2010;(3):CD007944.
66.
Agorastos A, Marmar CR, Otte C. Immediate and early behavioral interventions for the prevention of acute and posttraumatic stress disorder. Curr Opin Psychiatry. 2011;24(6):526–32.PubMed
67.
Ursano RJ, Bell C, Eth S, et al. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Am J Psychiatry. 2004;161(11 Suppl):3–31.PubMed
68.
National Collaborating Centre for Mental Health (Great Britain), National Institute for Clinical Excellence (Great Britain). Post-traumatic stress disorder: the management of PTSD in adults and children in primary and secondary care. National clinical practice guideline. 2005(no 26):vii.
69.
Jackson JL, O’Malley PG, Kroenke K. Antidepressants and cognitive-behavioral therapy for symptom syndromes. CNS Spectr. 2006;11(3):212–22.PubMed
70.
Kroenke K. Efficacy of treatment for somatoform disorders: a review of randomized controlled trials. Psychosom Med. 2007;69(9):881–8.PubMed
71.
Lowe B, Spitzer RL, Williams JB, et al. Depression, anxiety and somatization in primary care: syndrome overlap and functional impairment. Gen Hosp Psychiatry. 2008;30(3):191–9.PubMed
72.
Fink P, Rosendal M. Recent developments in the understanding and management of functional somatic symptoms in primary care. Curr Opin Psychiatry. 2008;21(2):182–8.PubMed
73.
Smith GR. The epidemiology and treatment of depression when it coexists with somatoform disorders, somatization, or pain. Gen Hosp Psychiatry. 1992;14(4):265–72.PubMed
74.
Janca A, Isaac M, Ventouras J. Towards better understanding and management of somatoform disorders. Int Rev Psychiatry. 2006;18(1):5–12.PubMed
75.
Arnold LM. Management of psychiatric comorbidity in fibromyalgia. Curr Psychiatry Rep. 2006;8(3):241–5.PubMed
76.
Arnold LM. Management of fibromyalgia and comorbid psychiatric disorders. J Clin Psychiatry. 2008;69(Suppl 2):14–9.PubMed
77.
Saarto T, Wiffen PJ. Antidepressants for neuropathic pain: a Cochrane review. J Neurol Neurosurg Psychiatry. 2010;81(12):1372–3.PubMed
78.
National Institute for Clinical Excellence (NICE). Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): diagnosis and management of CFS/ME in adults and children. London: National Institute for Clinical Excellence; 2007.
79.
National Institute for Clinical Excellence (NICE). Irritable bowel syndrome in adults: Diagnosis and management of irritable bowel syndrome in primary care. London: National Institute for Clinical Excellence; 2008.
80.
Avellaneda Fernandez A, Perez Martin A, Izquierdo Martinez M, et al. Chronic fatigue syndrome: aetiology, diagnosis and treatment. BMC Psychiatry. 2009;9(Suppl 1):S1.PubMed
81.
Kreijkamp-Kaspers S, Brenu EW, Marshall S, et al. Treating chronic fatigue syndrome—a study into the scientific evidence for pharmacological treatments. Aust Fam Physician. 2011;40(11):907–12.PubMed
82.
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.PubMed
83.
Lopez D, Mathers D, Ezzati M, et al. Global burden of disease and risk factors. New York: Oxford University Press and The World Bank; 2006.
84.
Sarna A, Pujari S, Sengar AK, et al. Adherence to antiretroviral therapy & its determinants amongst HIV patients in India. Indian J Med Res. 2008;127(1):28–36.PubMed
85.
Ronalds C, Creed F, Stone K, et al. Outcome of anxiety and depressive disorders in primary care. Br J Psychiatry. 1997;171:427–33.PubMed
86.
Busnello ED, Tannous L, Gigante L, et al. Diagnostic reliability in mental disorders of the International Classification of Diseases in primary care. Rev Saude Publica. 1999;33(5):487–94.PubMed
87.
MariJde J, Iacoponi E, Williams P, et al. Detection of psychiatric morbidity in the primary medical care setting in Brazil. Rev Saude Publica. 1987;21(6):501–7.
88.
Juruena MF, Calil HM, Fleck MP, et al. Melancholia in Latin American studies: a distinct mood disorder for the ICD-11. Rev Bras Psiquiatr. 2011;33(Suppl 1):S37–58.PubMed
89.
Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746–58.PubMed
90.
National Collaborating Centre for Mental Health (Great Britain), National Institute for Health and Clinical Excellence (Great Britain), Royal College of Psychiatrists., et al. Depression: the treatment and management of depression in adults. Updated ed. London: British Psychological Society and the Royal College of Psychiatrists; 2010.
91.
Hetrick S, Merry S, McKenzie J, et al. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database Syst Rev. 2007;(3):CD004851.
92.
Patel V, Chisholm D, Rabe-Hesketh S, et al. Efficacy and cost-effectiveness of drug and psychological treatments for common mental disorders in general health care in Goa, India: a randomised, controlled trial. Lancet. 2003;361(9351):33–9.PubMed
93.
Rojas G, Fritsch R, Solis J, et al. Treatment of postnatal depression in low-income mothers in primary-care clinics in Santiago, Chile: a randomised controlled trial. Lancet. 2007;370(9599):1629–37.PubMed
94.
Kaymaz N, van Os J, Loonen AJ, et al. Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry. 2008;69(9):1423–36.PubMed
95.
Fleck MP, Berlim MT, Lafer B, et al. Review of the guidelines of the Brazilian Medical Association for the treatment of depression (Complete version). Rev Bras Psiquiatr. 2009;31(Suppl 1):S7–17.PubMed
96.
Fleck MP, Lafer B, Sougey EB, et al. Guidelines of the Brazilian Medical Association for the treatment of depression (complete version). Rev Bras Psiquiatr. 2003;25(2):114–22.PubMed
97.
Barbui C, Cipriani A, Patel V, et al. Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis. Br J Psychiatry. 2011;198(1):11–6 sup 1.PubMed
98.
Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45.PubMed
99.
100.
Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64(5):543–52.PubMed
101.
Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241–51.PubMed
102.
Strakowski SM, DelBello MP. The co-occurrence of bipolar and substance use disorders. Clin Psychol Rev. 2000;20(2):191–206.
103.
Batista TA, Baes CVW, Juruena MF. Efficacy of psychoeducation in bipolar patients: systematic review of randomized trials. Psychol Neurosci. 2011;4(3):409–16.
104.
Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11(3):225–55.PubMed
105.
de Jesus MJ, Razzouk D, Thara R, et al. Packages of care for schizophrenia in low- and middle-income countries. PLoS Med. 2009;6(10):e1000165.PubMed
106.
Lora A, Kohn R, Levav I, et al. Service availability and utilization and treatment gap for schizophrenic disorders: a survey in 50 low- and middle-income countries. Bull World Health Organ. 2012;90(1):47–54 A–B.PubMed
107.
Bushe CJ, Taylor M, Haukka J. Mortality in schizophrenia: a measurable clinical endpoint. J Psychopharmacol. 2010;24(4 Suppl):17–25.PubMed
108.
Saha S, Chant D, Welham J, et al. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141.PubMed
109.
Walley J, Lawn JE, Tinker A, et al. Primary health care: making Alma-Ata a reality. Lancet. 2008;372(9642):1001–7.PubMed
110.
Xiong W, Phillips MR, Hu X, et al. Family-based intervention for schizophrenic patients in China. A randomised controlled trial. Br J Psychiatry. 1994;165(2):239–47.PubMed
111.
Healey A, Knapp M, Astin J, et al. Cost-effectiveness evaluation of compliance therapy for people with psychosis. Br J Psychiatry. 1998;172:420–4.PubMed
112.
Saxena S, Thornicroft G, Knapp M, et al. Resources for mental health: scarcity, inequity, and inefficiency. Lancet. 2007;370(9590):878–89.PubMed
113.
Chisholm D, Gureje O, Saldivia S, et al. Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis. Bull World Health Organ. 2008;86(7):542–51.PubMed
114.
Brietzke E, Araripe Neto AG, Dias A, et al. Early intervention in psychosis: a map of clinical and research initiatives in Latin America. Rev Bras Psiquiatr. 2011;33(Suppl 2):s213–24.PubMed
115.
Rosenbloom M. Chlorpromazine and the psychopharmacologic revolution. JAMA. 2002;287(14):1860–1.PubMed
116.
Kane JM. An evidence-based strategy for remission in schizophrenia. J Clin Psychiatry. 2008;69(Suppl 3):25–30.PubMed
117.
Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157(4):514–20.PubMed
118.
American Psychiatry Association (APA). Practice guideline for the treatment of patients with schizophrenia, 2nd edn. Washington (DC): American Psychiatric Press; 2004.
119.
Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. World J Biol Psychiatry. 2005;6(3):132–91.PubMed
120.
Royal Australian, New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia, Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry. 2005;39(1–2):1–30.
121.
Joy CB, Adams CE, Lawrie SM. Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev. 2006;(4):CD003082.
122.
Thornley B, Rathbone J, Adams CE, et al. Chlorpromazine versus placebo for schizophrenia. Cochrane Database Syst Rev. 2003;(2):CD000284.
123.
Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085–97.PubMed
124.
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–23.PubMed
125.
Huskamp HA. Prices, profits, and innovation: examining criticisms of new psychotropic drugs’ value. Health Aff (Millwood). 2006;25(3):635–46.
126.
Stahl SM, Grady MM. Stahl’s essential psychopharmacology: the prescriber’s guide. 4th ed. Cambridge: Cambridge University Press; 2011.
127.
Lehman AF, Steinwachs DM. Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr Bull. 1998;24(1):11–20 discussion 32.PubMed
128.
Leucht S, Heres S, Kissling W, et al. Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol. 2011;14(2):269–84.PubMed
129.
Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71–93.PubMed
130.
Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993;329(3):162–7.PubMed
131.
Velligan DI, Diamond PM, Mintz J, et al. The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophr Bull. 2008;34(3):483–93.PubMed
132.
Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull. 1997;23(4):637–51.PubMed
133.
Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241–7.PubMed
134.
David A, Adams CE, Eisenbruch M, et al. Depot fluphenazine decanoate and enanthate for schizophrenia. Cochrane Database Syst Rev. 2005;(1):CD000307.
135.
Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia—a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127(1–3):83–92.PubMed
136.
National Collaborating Centre for Mental Health (NCCMH), National Institute for Clinical Excellence (Great Britain). Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. Updated edition. Leicester and London: The British Psychological Society and the Royal College of Psychiatrists; 2010.
137.
Hofer A, Kemmler G, Eder U, et al. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry. 2004;65(7):932–9.PubMed
138.
Swanson SA, Crow SJ, Le Grange D, et al. Prevalence and correlates of eating disorders in adolescents. Results from the national comorbidity survey replication adolescent supplement. Arch Gen Psychiatry. 2011;68(7):714–23.PubMed
139.
Smink FR, van Hoeken D, Hoek HW. Epidemiology of eating disorders: incidence, prevalence and mortality rates. Curr Psychiatry Rep. 2012;14(4):406–14.PubMed
140.
Hay P. The epidemiology of eating disorder behaviors: an Australian community-based survey. Int J Eat Disord. 1998;23(4):371–82.PubMed
141.
Hudson JI, Hiripi E, Pope HG Jr, et al. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007;61(3):348–58.PubMed
142.
Grucza RA, Przybeck TR, Cloninger CR. Prevalence and correlates of binge eating disorder in a community sample. Compr Psychiatry. 2007;48(2):124–31.PubMed
143.
Striegel-Moore RH, Dohm FA, Kraemer HC, et al. Eating disorders in white and black women. Am J Psychiatry. 2003;160(7):1326–31.PubMed
144.
Hay PJ, Mond J, Buttner P, et al. Eating disorder behaviors are increasing: findings from two sequential community surveys in South Australia. PLoS One. 2008;3(2):e1541.PubMed
145.
Chen H, Jackson T. Prevalence and sociodemographic correlates of eating disorder endorsements among adolescents and young adults from China. Eur Eat Disord Rev. 2008;16(5):375–85.PubMed
146.
de Souza Ferreira JE, da Veiga GV. Eating disorder risk behavior in Brazilian adolescents from low socio-economic level. Appetite. 2008;51(2):249–55.PubMed
147.
Chandra PS, Abbas S, Palmer R. Are eating disorders a significant clinical issue in urban India? A survey among psychiatrists in Bangalore. Int J Eat Disord. 2012;45(3):443–6.PubMed
148.
Olesen J, Gustavsson A, Svensson M, et al. The economic cost of brain disorders in Europe. Eur J Neurol. 2012;19(1):155–62.PubMed
149.
American Psychiatric Association. Diagnostic criteria from DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000.
150.
Keel PK, Brown TA, Holland LA, et al. Empirical classification of eating disorders. Annu Rev Clin Psychol. 2012;8:381–404.
151.
Striegel-Moore RH, Bulik CM. Risk factors for eating disorders. Am Psychol. 2007;62(3):181–98.PubMed
152.
Khandelwal SK, Sharan P, Saxena S. Eating disorders: an Indian perspective. Int J Soc Psychiatry. 1995;41(2):132–46.PubMed
153.
Lee S, Lee AM, Ngai E, et al. Rationales for food refusal in Chinese patients with anorexia nervosa. Int J Eat Disord. 2001;29(2):224–9.PubMed
154.
Viernes N, Zaidan ZA, Dorvlo AS, et al. Tendency toward deliberate food restriction, fear of fatness and somatic attribution in cross-cultural samples. Eat Behav. 2007;8(3):407–17.PubMed
155.
Treasure J, Claudino AM, Zucker N. Eating disorders. Lancet. 2010;375(9714):583–93.PubMed
156.
Attia E, Kaplan AS, Walsh BT, et al. Olanzapine versus placebo for out-patients with anorexia nervosa. Psychol Med. 2011;41(10):2177–82.PubMed
157.
Bacaltchuk J, Hay P. Antidepressants versus placebo for people with bulimia nervosa. Cochrane Database Syst Rev. 2003;(4):CD003391.
158.
Hay PJ, Claudino AM. Bulimia nervosa. Clin Evid (Online). 2010;07:1009.
159.
Reas DL, Grilo CM. Review and meta-analysis of pharmacotherapy for binge-eating disorder. Obesity (Silver Spring). 2008;16(9):2024–38.
160.
Stefano SC, Bacaltchuk J, Blay SL, et al. Antidepressants in short-term treatment of binge eating disorder: systematic review and meta-analysis. Eat Behav. 2008;9(2):129–36.PubMed
161.
Hay PJ, Claudino AM. Clinical psychopharmacology of eating disorders: a research update. Int J Neuropsychopharmacol. 2012;15(2):209–22.PubMed
162.
Horne RL, Ferguson JM, Pope HG Jr, et al. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry. 1988;49(7):262–6.PubMed
163.
Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Fluoxetine Bulimia Nervosa Collaborative Study Group. Arch Gen Psychiatry. 1992;49(2):139–47.
164.
Romano SJ, Halmi KA, Sarkar NP, et al. A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am J Psychiatry. 2002;159(1):96–102.PubMed
165.
Grilo CM, Masheb RM, Wilson GT. Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison. Biol Psychiatry. 2005;57(3):301–9.PubMed
166.
McElroy SL, Casuto LS, Nelson EB, et al. Placebo-controlled trial of sertraline in the treatment of binge eating disorder. Am J Psychiatry. 2000;157(6):1004–6.PubMed
167.
Nickel C, Tritt K, Muehlbacher M, et al. Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial. Int J Eat Disord. 2005;38(4):295–300.PubMed
168.
McElroy SL, Hudson JI, Capece JA, et al. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry. 2007;61(9):1039–48.PubMed
169.
Claudino AM, de Oliveira IR, Appolinario JC, et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry. 2007;68(9):1324–32.PubMed
170.
Hay PP, Bacaltchuk J, Stefano S, et al. Psychological treatments for bulimia nervosa and binging. Cochrane Database Syst Rev. 2009;(4):CD000562.
171.
United Nations Office on Drug and Crime (UNODC). Vienna World Drug Report; 2011.
172.
Buckingham E, Schrage E, Cournos F. Why the treatment of mental disorders is an important component of HIV prevention among people who inject drugs. Adv Prev Med. 2013;2013:690386.PubMed
173.
Miller WR, Forcehimes A, Zweben A. Treating addiction: a guide for professionals. New York: Guilford Press; 2011.
174.
May PA, Brooke L, Gossage JP, et al. Epidemiology of fetal alcohol syndrome in a South African community in the Western Cape Province. Am J Public Health. 2000;90(12):1905–12.PubMed
175.
Jupp B, Lawrence AJ. New horizons for therapeutics in drug and alcohol abuse. Pharmacol Ther. 2010;125(1):138–68.PubMed
176.
Shorter D, Kosten TR. Novel pharmacotherapeutic treatments for cocaine addiction. BMC Med. 2011;9:119.PubMed
177.
Addolorato G, Leggio L, Hopf FW, et al. Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation. Neuropsychopharmacology. 2012;37(1):163–77.PubMed
178.
Segatto ML, Andreoni S, de Souza e Silva R. Brief motivational interview and educational brochure in emergency room settings for adolescents and young adults with alcohol-related problems: a randomized single-blind clinical trial. Rev Bras Psiquiatr. 2011;33(3):225–33.PubMed
179.
Saitz R, O’Malley SS. Pharmacotherapies for alcohol abuse: withdrawal and treatment. Med Clin N Am. 1997;81(4):881–907.PubMed
180.
Raupach T, van Schayck CP. Pharmacotherapy for smoking cessation: current advances and research topics. CNS Drugs. 2011;25(5):371–82.PubMed
181.
Hays JT, Ebbert JO. Adverse effects and tolerability of medications for the treatment of tobacco use and dependence. Drugs. 2010;70(18):2357–72.PubMed
182.
Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol. 2003;16(2):165–70.PubMed
183.
Burneo JG, Tellez-Zenteno J, Wiebe S. Understanding the burden of epilepsy in Latin America: a systematic review of its prevalence and incidence. Epilepsy Res. 2005;66(1–3):63–74.PubMed
184.
Fernandes PT, Salgado PC, Noronha AL, et al. Epilepsy stigma perception in an urban area of a limited-resource country. Epilepsy Behav. 2007;11(1):25–32.PubMed
185.
de Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. Epilepsy Behav. 2008;12(4):540–6.PubMed
186.
Leonardi M, Ustun TB. The global burden of epilepsy. Epilepsia. 2002;43(Suppl 6):21–5.PubMed
187.
Institute of Medicine (U.S.). Committee on the Public Health Dimensions of the Epilepsies, England MJ. Epilepsy across the spectrum: promoting health and understanding. Washington, DC: National Academies Press; 2012.
188.
Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1989;30(4):389–99.
189.
Smith DB, Mattson RH, Cramer JA, et al. Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone. Epilepsia. 1987;28(Suppl 3):S50–8.PubMed
190.
Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol. 2011;10(5):446–56.PubMed
191.
Sirven JI, Sperling M, Wingerchuk DM. Early versus late antiepileptic drug withdrawal for people with epilepsy in remission. Cochrane Database Syst Rev. 2001;(3):CD001902.
192.
Insel TR, Wang PS. Rethinking mental illness. JAMA. 2010;303(19):1970–1.PubMed
193.
Heuzenroeder L, Donnelly M, Haby MM, et al. Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. Aust N Z J Psychiatry. 2004;38(8):602–12.PubMed
194.
Laxminarayan R, Mills AJ, Breman JG, et al. Advancement of global health: key messages from the Disease Control Priorities Project. Lancet. 2006;367(9517):1193–208.PubMed
195.
Pike KM, Borovoy A. The rise of eating disorders in Japan: issues of culture and limitations of the model of “westernization”. Cult Med Psychiatry. 2004;28(4):493–531.PubMed
196.
Becker AE. Television, disordered eating, and young women in Fiji: negotiating body image and identity during rapid social change. Cult Med Psychiatry. 2004;28(4):533–59.PubMed
197.
Kayano M, Yoshiuchi K, Al-Adawi S, et al. Eating attitudes and body dissatisfaction in adolescents: cross-cultural study. Psychiatry Clin Neurosci. 2008;62(1):17–25.PubMed
198.
Raw M, McNeill A, Murray R. Case studies of tobacco dependence treatment in Brazil, England, India, South Africa and Uruguay. Addiction. 2010;105(10):1721–8.PubMed
199.
Benegal V, Chand PK, Obot IS. Packages of care for alcohol use disorders in low- and middle-income countries. PLoS Med. 2009;6(10):e1000170.PubMed
200.
Kimberly JR, McLellan AT. The business of addiction treatment: a research agenda. J Subst Abuse Treat. 2006;31(3):213–9.PubMed
201.
Sorsdahl KR, Stein DJ. Knowledge of and stigma associated with mental disorders in a South african community sample. J Nerv Ment Dis. 2010;198(10):742–7.PubMed
202.
Meyer AC, Dua T, Ma J, et al. Global disparities in the epilepsy treatment gap: a systematic review. Bull World Health Organ. 2010;88(4):260–6.PubMed
Metadata
Title
Pharmacological and Psychosocial Management of Mental, Neurological and Substance Use Disorders in Low- and Middle-Income Countries: Issues and Current Strategies
Authors
Jair de Jesus Mari
Luís Fernando Tófoli
Cristiano Noto
Li M. Li
Alessandra Diehl
Angélica M. Claudino
Mario F. Juruena
Publication date
01-09-2013
Publisher
Springer International Publishing
Published in
Drugs / Issue 14/2013
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-013-0113-4

Other articles of this Issue 14/2013

Drugs 14/2013 Go to the issue

R&D Insight Report

Dolutegravir: First Global Approval

Therapy in Practice

Optimal Pharmacotherapeutic Management of Hormone-Sensitive Metastatic Prostate Cancer

Adis Drug Evaluation

Ocriplasmin: A Review of Its Use in Patients with Symptomatic Vitreomacular Adhesion

Review Article

Update on the Management of Postoperative Nausea and Vomiting

Adis Drug Evaluation

Inactivated Quadrivalent Split-Virus Seasonal Influenza Vaccine (Fluarix® Quadrivalent): A Review of Its Use in the Prevention of Disease Caused by Influenza A and B

Adis Drug Evaluation

Ivacaftor: A Review of Its Use in Patients with Cystic Fibrosis